Can a weekly drug combo outsmart resistant lymphoma?
NCT ID NCT01703949
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 pilot study tests whether giving brentuximab vedotin weekly, alone or with nivolumab, can help people with CD30+ lymphoma whose cancer stopped responding to the standard every-3-week dosing. The study enrolls 28 adults with relapsed or refractory Hodgkin or non-Hodgkin lymphoma. The goal is to see if the new schedule can shrink tumors in at least 20% (with brentuximab alone) or 40% (with the combination) of patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brentuximab vedotin (a drug that targets cancer cells) and nivolumab (an immunotherapy that helps the immune system attack cancer)
- What this could lead to
- If successful, this could offer a new treatment option for people with CD30+ lymphoma whose cancer no longer responds to standard brentuximab vedotin dosing.
- What could go wrong
- This is a small, early-phase pilot study with only 28 participants. The response rate targets are modest (20-40%), and the results may not apply to all patients. Side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD30+ LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy shows promise for tough lymphoma cases
- Supercharged immune cells aim to stop lymphoma comeback
- Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
- Supercharged immune cells take on tough lymphoma
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- Blood cancer transplant study tests safer GVHD prevention